Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis. It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. It is produced in Chinese…
Community, Culture, Applications & Research
Explore the main themes, entities and connections around Dornase alfa. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
dornase alfa dna fibrosis cystic human pulmozyme viscosity legal status function recombinant selectively cleaves sputum mucus reduces clearance secretions produced
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Dornase alfa | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Dornase alfa | ATC code | R05CB13 (WHO) | 1.00 | infobox |
| Dornase alfa | CAS Number | 143831-71-4 N | 1.00 | infobox |
| Dornase alfa | ChemSpider | none | 1.00 | infobox |
| Dornase alfa | CompTox Dashboard (EPA) | DTXSID801010888 | 1.00 | infobox |
| Dornase alfa | DrugBank | DB00003 Y | 1.00 | infobox |
| Dornase alfa | ECHA InfoCard | 100.029.685 | 1.00 | infobox |
| Dornase alfa | Formula | C1321H1999N339O396S9 | 1.00 | infobox |
| Dornase alfa | KEGG | D03896 | 1.00 | infobox |
| Dornase alfa | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Dornase alfa | Legal status | CA: ℞-only / Schedule D | 1.00 | infobox |
| Dornase alfa | Legal status | US: ℞-only | 1.00 | infobox |
| Dornase alfa | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Dornase alfa | License data | US DailyMed: Dornase alfa | 1.00 | infobox |
| Dornase alfa | MedlinePlus | a694002 | 1.00 | infobox |
| Dornase alfa | Molar mass | 29254.04 g·mol−1 | 1.00 | infobox |
| Dornase alfa | Pregnancy category | AU: B1 | 1.00 | infobox |
| Dornase alfa | Routes of administration | Inhalation | 1.00 | infobox |
| Dornase alfa | Trade names | Pulmozyme | 1.00 | infobox |
| Dornase alfa | UNII | 953A26OA1Y | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.